查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1985589

CAR T 細胞療法市場：2026-2032 年全球市場預測（按適應症、細胞來源、代數、治療線、標靶抗原和最終用戶分類）。

CAR T-cell Therapy Market by Indication, Cell Source, Generation, Line Of Therapy, Target Antigen, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 CAR-T 細胞療法市場在 2025 年的價值為 51.9 億美元，在 2026 年成長至 59.8 億美元，到 2032 年達到 148.7 億美元，複合年成長率為 16.20%。

主要市場統計數據
基準年 2025 51.9億美元
預計年份：2026年 59.8億美元
預測年份 2032 148.7億美元
複合年成長率 (%) 16.20%

一份簡明的 CAR T 細胞療法策略指南，整合了科學進步、生產實際情況、監管趨勢和商業性准入等方面的考量。

CAR-T細胞療法目前正處於前沿免疫腫瘤學和複雜商業性實施的交匯點。本執行摘要對CAR-T領域的現況進行了綜合分析，包括臨床進展、轉化創新、監管趨勢、生產技術成熟度以及不斷演變的醫療服務模式。本文件旨在幫助企業主管、臨床負責人、投資者和政策制定者了解影響研發重點和營運決策的各項因素。

技術、監管、製造和商業變革如何重塑 CAR-T 療法的發展路徑和患者獲得治療的模式。

CAR-T細胞療法正在經歷一系列變革，這些變革並非僅僅是對產品的漸進式改進，而是從根本上改變了其研發和給藥的結構。載體工程、共刺激結構域選擇和抗原標靶化的進步，在拓展治療範圍的同時，也提升了其安全性和持久性。這些技術進步與製造創新相輔相成，例如分散式和自動化平台，它們縮短了生產週期，降低了每劑藥物的操作複雜性。隨著這些技術變革的推進，新的商業模式正在湧現，這些模式將集中化的專業知識與臨床應用相結合。

應對 2025 年關稅變化的營運和策略措施、重組供應鏈韌性、製造地決策和臨床試驗物流。

美國於2025年實施的新關稅措施為先進細胞療法的經濟性和物流帶來了特定的變數。對進口原料、一次性組件和某些生物製程設備徵收的關稅將增加上游工程成本，並為供應商選擇帶來不確定性。這種情況促使製造商和臨床中心重新評估籌資策略，尋找替代供應商，並考慮加強關鍵供應鏈的垂直整合。短期內，由於合約團隊需要評估關稅的影響並協商修訂後的條款，採購週期將會延長。

基於細分的洞察揭示了適應症、細胞來源、世代、治療系、抗原標靶和醫療保健環境如何決定開發和商業化途徑。

詳細的市場細分揭示了治療和給藥領域中一些微妙的促進因素和明顯的機會領域。就適應症而言，此市場涵蓋白血病（白血病本身又細分為急性淋巴性白血病和急性骨髓性白血病）、多發性骨髓瘤和非何傑金氏淋巴瘤（特別是瀰漫性大B細胞淋巴瘤、濾泡性淋巴瘤和套細胞淋巴瘤等特定臨床亞型）。每種適應症都有其自身的療效預期、安全性考量和證據要求，這些因素都會影響臨床試驗設計和商業化策略。就細胞來源而言，異體治療方法具有「即用型」給藥和縮短治療啟動時間的潛力，而自體療法在個人化生產符合既定安全性和有效性先例的領域仍然十分重要。

區域法規環境、生產策略和醫療保健服務體系如何導致全球市場上 CAR-T 療法的取得途徑有差異？

區域趨勢對監管預期、生產策略和醫療服務模式有著深遠的影響。在美洲，密集的專科治療中心網路、歷來充滿活力的風險投資生態系統以及靈活的監管路徑，促進了早期臨床導入和商業化策略的實施，這些策略強調本土生產和真實世界數據（REW）的生成。相較之下，歐洲、中東和非洲地區則呈現出管理體制和報銷機制的多元化格局，需要針對每個地區制定具體的衛生經濟學論證和立足本地的參與計畫。同時，這些地區也為能夠服務多個市場的區域性製造地提供了發展機會。

透過製造規模、結構創新和綜合商業性支援來創造競爭優勢的企業策略和合作模式。

CAR-T 生態系統中的主要企業正致力於建立多元化的產品組合，涵蓋建構設計、抗原標靶化和生產流程等方面，同時積極尋求策略合作夥伴關係，以確保供應鏈穩定並拓展臨床應用。產業相關人員正投資於模組化、自動化生產平台，以縮短週期時間並提高可重複性，並積極與學術機構和契約製造組織 (CMO) 合作，以擴大產能。多家公司正透過專注於提高持久性、降低毒性和實現多抗原標靶化以應對抗原逃脫的下一代工程技術來實現差異化競爭。

一項旨在透過加強製造業韌性、證據生成、支付方合作以及擴大檢測設施，加速行業領導者永續獲取的行動計劃。

行業領導者應優先進行一系列合作，將科學創新與營運擴充性和市場進入準備工作相結合。首先，投資建立靈活的生產架構，支援終端來源和異體來源的工作流程，從而能夠快速回應不斷變化的需求和關稅相關的供應波動。其次，建立健全的品質體系，並為關鍵試劑和一次性組件提供冗餘的供應保障，以最大限度地減少生產中斷，確保患者治療計劃的順利進行。第三，透過與治療中心和註冊機構合作，加速真實世界數據（REW）的創建，記錄長期療效和安全性訊號，為醫保報銷談判奠定基礎。

採用透明的混合方法，結合相關人員訪談、文獻整合、監管審查和營運案例研究，得出了切實可行的建議。

本研究整合了一手和二手資料，以當代科學和商業性實踐為基礎，得出實證見解。一手資料包括對臨床研究人員、生產專家、支付方和治療中心營運經理的結構化訪談，旨在了解生產能力限制、供應鏈風險和推廣障礙等方面的實際觀點。二手資料分析涵蓋同行評審文獻、監管指導文件、會議記錄和企業資訊披露，以全面檢驗臨床療效、安全性趨勢和技術進步。

策略挑戰的整合表明，需要提高製造韌性、產生證據並與支付方合作，以滿足科學預期並實現更廣泛的獲取。

總之，CAR-T細胞療法正處於一個關鍵的轉折點，科學創新、生產能力和商業策略必須協調一致，才能為患者帶來更廣泛的益處。結構工程和下一代設計方面的技術進步不斷拓展治療的可能性，但對供應鏈和政策變化的運作應對將決定這些治療方法成為常規治療方案的速度。監管的柔軟性以及支付方參與基於結果的模式的意願，是將臨床獲益轉化為永續可及性的關鍵途徑。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 CAR-T細胞療法市場：依適應症分類

  • 白血病
    • 急性淋巴性白血病
    • 急性骨髓性白血病
  • 多發性骨髓瘤
  • 非何傑金氏淋巴瘤
    • 瀰漫性大B細胞淋巴瘤
    • 濾泡性淋巴瘤
    • 套細胞淋巴瘤

第9章 CAR-T細胞療法市場（依細胞來源分類）

  • 同種
  • 自有住房

第10章 CAR-T細胞療法市場（按世代分類）

  • 第一代
  • 第四代
  • 第二代
  • 第三代

第11章：依治療階段分類的CAR-T細胞療法市場

  • 主要治療
  • 復發/難治性

第12章 CAR-T細胞療法市場（以標靶抗原分類）

  • BCMA
  • CD19

第13章 CAR-T細胞療法市場：依最終用戶分類

  • 學術研究機構
  • 醫院
  • 門診癌症治療中心
  • 專科診所

第14章 CAR-T細胞療法市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 CAR-T細胞療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 CAR-T細胞療法市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 美國CAR-T細胞療法市場

第18章 中國CAR-T細胞療法市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbClon Inc.
  • Adaptimmune Therapeutics
  • Allogene Therapeutics
  • Anixa Biosciences, Inc.
  • Autolus Therapeutics
  • Baylor College of Medicine
  • Bellicum Pharmaceuticals, Inc
  • BioAtla Inc.
  • Bluebird Bio
  • Caribou Biosciences, Inc.
  • Cellectis SA
  • Celyad Oncology
  • DH Life Sciences, LLC.
  • Fate Therapeutics, Inc.
  • Immatics NV
  • Innovative Cellular Therapeutics
  • JW Therapeutics,Co., Ltd.
  • Legend Biotech Inc.
  • Miltenyi Biotec
  • Novartis AG
  • Poseida Therapeutics
  • Precision BioSciences
  • Sana Biotechnology, Inc.
  • Sorrento Therapeutics
  • Tessa Therapeutics Pte Ltd.
  • uBriGene Biosciences Inc.
Product Code: MRR-1E2F1ED7E6AA

The CAR T-cell Therapy Market was valued at USD 5.19 billion in 2025 and is projected to grow to USD 5.98 billion in 2026, with a CAGR of 16.20%, reaching USD 14.87 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.19 billion
Estimated Year [2026] USD 5.98 billion
Forecast Year [2032] USD 14.87 billion
CAGR (%) 16.20%

A concise strategic orientation to CAR T-cell therapy integrating scientific progress, manufacturing realities, regulatory dynamics, and commercial access considerations

The landscape of CAR T-cell therapy sits at the intersection of cutting-edge immuno-oncology science and complex commercial execution. This executive summary synthesizes clinical progress, translational innovations, regulatory momentum, manufacturing maturation, and shifting care delivery models that collectively define the current state of CAR T field. It is intended to orient executives, clinical leaders, investors, and policy makers to the forces shaping development priorities and operational decisions.

Beginning with a succinct review of therapeutic mechanisms and indication-specific clinical performance, the summary transitions to pragmatic considerations such as manufacturing capacity, supply chain resilience, and evolving site-of-care dynamics. Throughout, emphasis rests on actionable insights that link scientific advances to commercial feasibility. The narrative highlights how modular manufacturing platforms, antigen selection strategies, and next-generation constructs are translating into differentiated clinical profiles and new usage paradigms. In parallel, payor engagement and real-world evidence generation are emerging as critical determinants of access and uptake.

Taken together, the introduction frames subsequent sections by clarifying how discrete technological, regulatory, and economic developments are converging to reshape CAR T strategy across stakeholders, supporting informed decisions about investment, partnership, and operational design.

How technical, regulatory, manufacturing, and commercial shifts are jointly reconfiguring CAR T development pathways and patterns of patient access

CAR T-cell therapy is undergoing a series of transformative shifts that extend beyond incremental product improvements to alter the structure of development and delivery. Advances in vector engineering, costimulatory domain selection, and antigen targeting are expanding therapeutic applicability while simultaneously influencing safety and durability profiles. These technical evolutions are complemented by manufacturing innovations such as decentralized and automated platforms that shorten production timelines and lower per-dose operational complexity. As these technical shifts progress, they create opportunities for novel commercial models that blend centralized expertise with point-of-care delivery.

Regulatory pathways are adapting in parallel, with agencies showing increasing willingness to consider real-world evidence and adaptive development strategies that balance expedited access with long-term safety monitoring. Meanwhile, health systems are recalibrating infrastructure to support CAR T administration outside of traditional inpatient settings, and payors are experimenting with outcome-based contracting to align cost and clinical benefit. Taken together, these shifts are driving a transition from single-product, high-cost interventions toward more scalable, evidence-driven programs that prioritize durable outcomes and broader patient access. Stakeholders that anticipate and align with these shifts will be better positioned to convert scientific leadership into sustained clinical and commercial impact.

Operational and strategic responses to 2025 tariff shifts that reshape supply chain resilience, manufacturing footprint decisions, and clinical trial logistics

The introduction of new United States tariff measures in 2025 has introduced a tangible variable into the economics and logistics of advanced cell therapies. Tariffs applied to imported raw materials, single-use components, and specific bioprocessing equipment increase upstream costs and create uncertainty in supplier selection. This dynamic incentivizes manufacturers and clinical centers to re-evaluate sourcing strategies, explore alternative suppliers, and consider increased vertical integration of critical supply chains. In the near term, procurement cycles lengthen as contracting teams assess tariff impacts and negotiate revised terms.

Beyond procurement, tariff-driven cost pressures influence decisions around manufacturing footprint. Organizations may accelerate investments in domestic manufacturing capacity to reduce exposure to cross-border duties, or they may pursue regional partnerships that localize key steps such as vector production and fill-finish operations. Clinical trial sponsors will need to revisit budgeting assumptions and may prioritize sites with proximate manufacturing or supply redundancy to mitigate logistical risk. In parallel, hospitals and outpatient centers that provide infusion services must adapt planning for consumable inventory and capital equipment procurement.

Taken together, tariffs in 2025 do not change the scientific promise of CAR T therapies, but they do alter operational calculus. Stakeholders who adopt proactive supply chain diversification, strategic onshoring where feasible, and collaborative contracting with suppliers will reduce disruption and preserve treatment continuity for patients while maintaining momentum in development and commercialization.

Segmentation-driven insights that reveal how indication, cell source, generation, therapeutic line, antigen targeting, and care settings define development and commercialization pathways

Detailed segmentation uncovers nuanced drivers and distinct opportunity spaces across therapeutic and delivery domains. By indication the market spans Leukemia, which itself is subdivided into Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, Multiple Myeloma, and Non Hodgkin Lymphoma with Diffuse Large B Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma representing specific clinical subtypes; each indication carries unique response expectations, safety considerations, and evidentiary needs that influence trial design and commercialization strategy. Considering cell source, therapies derived from Allogeneic sources offer the promise of off-the-shelf dosing and faster time-to-treatment, while Autologous approaches remain prominent where individualized manufacturing aligns with established safety and efficacy precedents.

Generational differentiation also shapes clinical and operational profiles; First Generation constructs established proof of concept, Second Generation products introduced optimized costimulatory domains, Third Generation approaches combine multiple signaling elements for enhanced persistence, and Fourth Generation designs incorporate engineered functionalities such as cytokine expression or safety switches to broaden therapeutic potential. Line of therapy segmentation, including Frontline versus Relapsed Refractory use, dictates trial endpoints and payer conversations since earlier-line adoption prioritizes safety and long-term benefit whereas relapsed refractory contexts emphasize rapid response. Target antigen selection, notably BCMA and CD19, continues to drive indication-specific strategies and companion diagnostics development. Finally, end user segmentation across Academic Research Institutes, Hospitals, Outpatient Oncology Centers, and Specialty Clinics determines where investments in training, infrastructure, and care pathways will be most impactful, influencing rollout sequencing and provider partnerships.

How regional regulatory environments, manufacturing strategies, and care delivery capacity are directing differentiated CAR T access across global markets

Regional dynamics exert a powerful influence on regulatory expectations, manufacturing strategy, and care delivery models. In the Americas, dense networks of specialized treatment centers, a historically active venture ecosystem, and flexible regulatory pathways have catalyzed early clinical adoption and commercialization strategies that emphasize domestic manufacturing and real-world evidence generation. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory regimes and heterogeneous reimbursement systems that require tailored health economic arguments and localized engagement plans, while also offering opportunities for regional manufacturing hubs that can serve multiple markets.

Asia-Pacific exhibits rapid capacity building, increasing domestic investment into cell therapy platforms, and an expanding pool of clinical trial sites that can accelerate patient accrual and comparative effectiveness research. Differences in infrastructure, workforce training, and reimbursement policy across these regions shape the pace and scale of access; as a result, manufacturers are adopting region-specific manufacturing footprints, regulatory strategies, and commercial partnerships to optimize launch sequencing and pricing models. Cross-regional collaboration, including licensing, co-development, and strategic manufacturing alliances, emerges as a practical pathway to reconcile global ambition with local realities and regulatory nuance.

Corporate strategies and collaborative models that drive competitive advantage through manufacturing scale, construct innovation, and integrated commercial support

Leading organizations in the CAR T ecosystem are advancing diversified portfolios across construct design, antigen targeting, and manufacturing modalities while pursuing strategic alliances to secure supply chains and broaden clinical reach. Industry participants are investing in modular, automated manufacturing platforms to reduce cycle times and improve reproducibility, and they are forging partnerships with academic centers and contract manufacturing organizations to expand capacity. Several companies are differentiating through next-generation engineering approaches that focus on enhancing persistence, reducing toxicities, and enabling multi-antigen targeting to address antigen escape.

At the same time, competitive dynamics reflect a balance between proprietary platform advantages and collaborative models that accelerate clinical development. Licensing agreements and co-development arrangements enable newer entrants to leverage established vector and manufacturing know-how, while incumbents seek to protect clinical differentiation through robust evidence generation and post-market surveillance. Commercial activities emphasize integrated value propositions that combine clinical training, reimbursement support, and outcomes tracking to de-risk adoption for health systems. As a result, competitive advantage increasingly derives from the ability to align scientific differentiation with scalable manufacturing and pragmatic commercialization support.

Action plans for industry leaders to link manufacturing resilience, evidence generation, payer engagement, and expanded site readiness to accelerate sustainable access

Industry leaders should prioritize a set of coordinated actions that connect scientific innovation with operational scalability and market access readiness. First, invest in flexible manufacturing architectures that support both autologous and allogeneic workflows, enabling rapid response to demand shifts and tariff-induced sourcing variability. Second, embed robust quality systems and supply redundancy for critical reagents and single-use components to minimize production interruptions and preserve patient schedules. Third, accelerate generation of real-world evidence by partnering with treatment centers and registries to document long-term outcomes and safety signals that underpin reimbursement discussions.

In parallel, companies should cultivate payer partnerships that explore outcome-based contracting and risk-sharing models aligned to durable response metrics, facilitating earlier adoption in frontline settings. From a clinical perspective, expand training programs and accreditation pathways to enable safe administration across a broader range of hospitals and outpatient oncology centers, thereby reducing time-to-treatment and improving patient access. Finally, adopt strategic regionalization for manufacturing and regulatory engagement that balances cost, speed-to-market, and local market access imperatives. These combined steps will strengthen resilience and align product value with health system needs, accelerating the conversion of scientific promise into patient benefit.

A transparent mixed-methods approach combining stakeholder interviews, literature synthesis, regulatory review, and operational case studies to inform practical recommendations

This research synthesized primary and secondary sources to produce evidence-based insights grounded in contemporary scientific and commercial practice. Primary inputs included structured interviews with clinical investigators, manufacturing experts, payers, and operational leaders across treatment centers to capture on-the-ground perspectives about capacity constraints, supply chain risks, and adoption barriers. Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, conference proceedings, and company disclosures to triangulate clinical efficacy, safety trends, and technological advancements.

Analytical methods combined thematic synthesis with comparative operational assessment to identify capacity bottlenecks and strategic responses. Case studies of manufacturing scale-up and decentralized production models informed practical recommendations. Throughout the methodology, emphasis was placed on transparency around data limitations, including the variable maturity of clinical evidence across indications and the evolving regulatory landscape. Sensitivity to regional regulatory differences and supply chain volatility guided scenario planning and risk mitigation suggestions. Ethical considerations and patient-centric outcomes remain central to the interpretive framework, and the research team employed rigorous validation steps to ensure credibility and relevance for decision-makers.

Synthesis of strategic imperatives showing that scientific promise requires manufacturing resilience, evidence generation, and payer engagement to achieve broader access

In conclusion, CAR T-cell therapy stands at a decisive inflection point where scientific innovation, manufacturing capability, and commercial strategy must align to deliver broader patient impact. Technical progress in construct engineering and next-generation designs continues to expand therapeutic potential, while operational responses to supply chain and policy changes will determine the pace at which those therapies become routine care options. Regulatory flexibility and payer willingness to engage around outcomes-based models are critical levers to translate clinical benefit into sustainable access.

Moving from promise to practice requires coordinated investments in manufacturing resilience, evidence generation, and clinical site readiness, together with proactive stakeholder engagement across regulators, payers, and providers. Organizations that synchronize technical differentiation with pragmatic operational design and regional strategy will capture the greatest clinical and commercial upside. Ultimately, the future of CAR T depends not only on molecular innovation but equally on the robustness of the systems that deliver these therapies to patients in need.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CAR T-cell Therapy Market, by Indication

  • 8.1. Leukemia
    • 8.1.1. Acute Lymphoblastic Leukemia
    • 8.1.2. Acute Myeloid Leukemia
  • 8.2. Multiple Myeloma
  • 8.3. Non Hodgkin Lymphoma
    • 8.3.1. Diffuse Large B Cell Lymphoma
    • 8.3.2. Follicular Lymphoma
    • 8.3.3. Mantle Cell Lymphoma

9. CAR T-cell Therapy Market, by Cell Source

  • 9.1. Allogeneic
  • 9.2. Autologous

10. CAR T-cell Therapy Market, by Generation

  • 10.1. First Generation
  • 10.2. Fourth Generation
  • 10.3. Second Generation
  • 10.4. Third Generation

11. CAR T-cell Therapy Market, by Line Of Therapy

  • 11.1. Frontline
  • 11.2. Relapsed Refractory

12. CAR T-cell Therapy Market, by Target Antigen

  • 12.1. BCMA
  • 12.2. CD19

13. CAR T-cell Therapy Market, by End User

  • 13.1. Academic Research Institutes
  • 13.2. Hospitals
  • 13.3. Outpatient Oncology Centers
  • 13.4. Specialty Clinics

14. CAR T-cell Therapy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. CAR T-cell Therapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. CAR T-cell Therapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States CAR T-cell Therapy Market

18. China CAR T-cell Therapy Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbClon Inc.
  • 19.6. Adaptimmune Therapeutics
  • 19.7. Allogene Therapeutics
  • 19.8. Anixa Biosciences, Inc.
  • 19.9. Autolus Therapeutics
  • 19.10. Baylor College of Medicine
  • 19.11. Bellicum Pharmaceuticals, Inc
  • 19.12. BioAtla Inc.
  • 19.13. Bluebird Bio
  • 19.14. Caribou Biosciences, Inc.
  • 19.15. Cellectis SA
  • 19.16. Celyad Oncology
  • 19.17. DH Life Sciences, LLC.
  • 19.18. Fate Therapeutics, Inc.
  • 19.19. Immatics N.V.
  • 19.20. Innovative Cellular Therapeutics
  • 19.21. JW Therapeutics,Co., Ltd.
  • 19.22. Legend Biotech Inc.
  • 19.23. Miltenyi Biotec
  • 19.24. Novartis AG
  • 19.25. Poseida Therapeutics
  • 19.26. Precision BioSciences
  • 19.27. Sana Biotechnology, Inc.
  • 19.28. Sorrento Therapeutics
  • 19.29. Tessa Therapeutics Pte Ltd.
  • 19.30. uBriGene Biosciences Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CAR T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CAR T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 163. GCC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 167. GCC CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 189. G7 CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 190. G7 CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 192. G7 CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 194. G7 CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 198. NATO CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 199. NATO CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 201. NATO CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 203. NATO CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)